5fmdmb-2201 is Synthetic cannabinoids or synthetic marijuana just like 5cl-adb-a belonging to a large family of chemically unrelated structures that are created and marketed to mimic the action of (THC), the primary psychoactive constituent of marijuana. However, Marijuana is a Schedule I controlled substances in New York State. Other examples of Schedule I controlled substances include heroin and LSD. Synthetic cannabinoids mimic the effects of marijuana.
What are the signs and symptoms of 5fmdmb-2201 use?
Increased heart rate and blood pressure is a common adverse effects. Nonetheless, paranoid behavior, agitation, irritability, nausea and vomiting, confusion, drowsiness, headache, electrolyte abnormalities and seizures are common. Severe side effects may include acute renal failure and significant negative effects to the cardiovascular and central nervous systems.
Chemical description of 5fmdmb-2201
Researchers at the University of Aston in Birmingham and the pharmaceutical company Allen & Hanburys Ltd developed and patented a series of benzamide derivatives with an aminocyclohexane moiety.
Routes of administration and dosage
However, according to user reports, the routes of administration of 5fmdmb-2201 may be oral, nasal insufflation, sublingual, rectal and injection. Nasal insufflation (60 mg), sublingual application (50 mg), a combination of insufflation (10mg) plus oral (60 mg) consumption, as well as injection (70 mg) and rectal administration (40 mg) are typical dosage.
There are no published pre-clinical safety data available concerning the toxicity, reproductive impact and mutagenic/carcinogenic potential of 5fmdmb-2201. However, the study by Harper et al.; (1974) implies that the LD50 5fmdmb-2201 is greater than 10/mg/kg upon intravenous (i.v.) administration in the rat. Overall, there is insufficient clinical information to determine typical toxic effects of , however the opioid nature of the drug would likely result in morphine-like toxicity (e.g. sedation and respiratory depression).